Inhibition of PLA2 signaling may represent an important signaling pathway to target for the treatment of Alzheimer's disease, to reduce the amount of APP that is released from neurons and decrease the burden of accumulation of toxic amyloid plaques. This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.